Effect of arsenic trioxide on uveal melanoma cell proliferation in vitro
- PMID: 17957129
- DOI: 10.1159/000109985
Effect of arsenic trioxide on uveal melanoma cell proliferation in vitro
Erratum in
- Ophthalmic Res. 2008;40(2):108. Shi, Guangpu [added]
Abstract
Aims: The aim of this study was to investigate the effect of arsenic trioxide (ATO) on the growth of cultured uveal melanoma cells (OCM-1 cell line).
Methods: Cultured OCM-1 cells were treated with 0.75-24 microM of ATO for 4-96 h. Cell viability was evaluated with the methylthiazoletetrazolium (MTT) assay as proliferation test. Apoptotic and necrotic cells were quantified using flow cytometry following Annexin-V/PI double stain. The cell morphology alteration was examined by light and electron transmission microscopy. To investigate the underlying mechanism of ATO-induced apoptosis and necrosis, glutathione peroxidase activity was measured, and mitochondrial membrane potentials were quantified using confocal microscopy.
Results: In the MTT assays, OCM-1 cell growth was inhibited at ATO concentrations of 1.5-24 microM. The 50% inhibitory concentration of ATO was 16.8 microM. At ATO concentrations of 12 and 24 microM, apoptosis and necrosis were induced after 24 h of incubation as shown by light and transmission electron microscopy. At ATO concentrations of 12 and 24 microM, the glutathione peroxidase activity was significantly (p < 0.05) reduced after 24 h of incubation, and the mitochondrial membrane potentials were significantly (p < 0.01) decreased after 4, 12 and 24 h of incubation.
Conclusion: ATO inhibited ocular melanoma cell line growth at concentrations of 1.5-24 microM of ATO in a dose- and time-dependent manner by inducing apoptosis and necrosis of the tumor cells. The concurringly decreased glutathione peroxidase activity and the reduced mitochondrial membrane potentials may be possible underlying mechanisms for the apoptosis and necrosis of the tumor cells.
(c) 2007 S. Karger AG, Basel.
Similar articles
-
A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.Pancreas. 2009 May;38(4):e114-23. doi: 10.1097/MPA.0b013e3181a0b6f2. Pancreas. 2009. PMID: 19342982
-
[In vitro study on inhibition of human choroidal melanoma OCM-1 cell line by arsenic trioxide].Zhonghua Yan Ke Za Zhi. 2005 Oct;41(10):887-91. Zhonghua Yan Ke Za Zhi. 2005. PMID: 16271172 Chinese.
-
Antitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration.Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1819-23. doi: 10.1167/iovs.08-2623. Epub 2008 Dec 5. Invest Ophthalmol Vis Sci. 2009. PMID: 19060284
-
Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia.Int J Oncol. 2005 Aug;27(2):537-45. Int J Oncol. 2005. PMID: 16010437
-
Effects of arsenic trioxide on cell death, reactive oxygen species and glutathione levels in different cell types.Int J Mol Med. 2010 Jan;25(1):121-8. Int J Mol Med. 2010. PMID: 19956910
Cited by
-
Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer.Drug Saf. 2019 Feb;42(2):263-279. doi: 10.1007/s40264-018-0777-5. Drug Saf. 2019. PMID: 30649745 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous